CDMO
33 recent notes from companies in this sector. 15 companies tracked.
Supriya Lifescience GM in judicial custody for NDPS export lapse
Company says no material impact on operations, citing isolated procedural lapse in a single export transaction.
Syngene names Biocon's Mittal as CEO; independence questions linger
Siddharth Mittal, who led Biocon's GLP-1 push, will take over from Peter Bains, but the insider appointment blurs corporate boundaries.
Jubilant Pharmova's ₹53.37 cr tax setback
Income tax rectification order disallows brought-forward losses at subsidiary Jubilant Biosys, but the company says it will appeal and sees no material impact.
Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
Rectification order restores ₹65.48 cr in tax losses for subsidiary Jubilant Generics, but the company continues to appeal the remaining amount on merits.
Acutaas Chemicals' facility raided by GST anti-evasion dept
CGST search at Sachin facility & registered office began Jun 22, still ongoing. Company says no material impact yet, but uncertainty remains for the ₹26,595 cr CDMO.
Anthem Biosciences promoter group member sells entire 3.05% stake
Aruna Ganesh sold her full 1,71,14,604 shares on June 18, 2026. The ₹44,771 cr CDMO now has one fewer direct promoter holder.
Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
No sterility concerns at key injectables unit, but 8 observations require a 15-day response. Spokane Line 3 expansion is the growth driver.
Cohance promoters pledge 54% of equity to refinance $285M debt
Jusmiral Holdings and Berhyanda have gone from zero encumbrance to pledging their entire stake. The loan amounts to 14.5% of market cap.
Hikal's Q4 profit sinks under ₹47 cr write-down; no FY27 guidance
Operating margins improved to 20.3% but a plant impairment and a USFDA warning letter are overshadowing the recovery.
Piramal Pharma's Dahej plant clears its last environmental hurdle
The Gujarat Pollution Control Board has permanently revoked its closure directions. The risk of a surprise shutdown at a key manufacturing hub is gone.
Supriya Lifescience posts 50% revenue jump, clears USFDA inspection
Quarterly revenue hit ₹277 crore, net profit rose 47% to ₹74 crore. The Lote facility received a VAI classification from the USFDA.
USFDA hits Jubilant's Montreal plant with a Warning Letter
The FDA found prior remediation efforts insufficient, escalating the site from 'Official Action Indicated' status. New drug approvals from the facility are now frozen.
Hikal's earnings release adds no new data to prior disclosures.
The company's latest press release provides qualitative commentary on its FY26 performance but contains no material financial information beyond what was already filed.
Hikal's latest investor presentation adds no new information
The company released a routine investor presentation for Q4 and FY26, but the document contains no material data beyond the previously disclosed earnings.
Hikal fills key division vacancy and closes internal probe
Ravi Khadabadi takes over the Crop Protection & Specialty Chemicals unit, while an investigation into employee irregularities concludes with no financial impact.
Hikal swings to a loss as USFDA issues and impairments bite
The company reported a net loss of ₹487 million for FY26, down from a profit of ₹909 million, while slashing its dividend payout by more than half.
Aarti Pharmalabs targets 40-50% CDMO growth as project pipeline shrinks
Management expects long-term revenue growth of 15-18% but faces near-term margin pressure from startup costs and raw material inflation.
Aarti Pharmalabs profit drops as finance costs and margins bite
The pharmaceutical firm reported a decline in annual profit to ₹176.20 crore, down from ₹238.03 crore in the previous year.
Aarti Pharmalabs profit slides as costs and forex losses mount
Standalone net profit fell to ₹62.03 crore in Q4, down from ₹88.85 crore a year ago, as finance costs and currency headwinds pressured margins.
Aarti Pharmalabs profit drops as derivative accounting error surfaces
Standalone net profit fell to ₹62.03 crore in Q4, while the company disclosed a ₹29.73 crore loss from a previously omitted derivative contract.
Dishman's debt refi plan is the headline, not the earnings beat
Q4 revenue rose 19% to ₹851 crore and FY26 profit jumped to ₹97.4 crore, but the call's real news is a proposed ₹800 crore refinancing with the promoter at 4%.
Blue Jet shelves ₹1,000 cr Vizag plan, CDMO pipeline shrinks to 4 projects
Management pivoted capex away from a flagship plant and disclosed a CDMO pipeline of just 4-5 projects, down from 20 active RFPs last quarter.
Jubilant Pharmova subsidiary lands ₹107.89 cr tax demand
A transfer pricing order for FY23 hits the subsidiary, forcing a ₹37.70 cr write-down of deferred tax assets.
Jubilant Pharmova pulls Spokane Line 3 timeline forward by two years
The company expects peak revenue of $80-90M sooner than planned, while the Montreal plant continues to burn cash until FY28.
Anthem Biosciences bets ₹1,200 cr on GLP-1 plant expansion
Management is doubling custom synthesis capacity to chase Indian GLP-1 demand after posting record quarterly revenue of ₹611 cr.
Jubilant Pharmova posts ₹8,280 cr revenue, adds oncology client to Montreal facility
FY26 revenue grew 14% while EBITDA rose 8%. The CDMO unit added a global oncology product and is remediating its Montreal plant.
Jubilant Pharmova names Ashish Mukkirwar as CFO
Arun Kumar Sharma steps down into an advisory role as the company works through regulatory hurdles at its Montreal facility.
Jubilant Pharmova profit halves to ₹3,975 m on Montreal remediation costs
Revenue grew 14.5% to ₹82,796 million, but net profit fell 52% as the company absorbed ₹535 million in costs to fix its Montreal facility.
Jubilant Pharmova profits halved to ₹397 cr as remediation costs weigh
Regulatory challenges at the Montreal site drag on bottom-line performance despite 14.5% revenue growth.
Laurus Labs lands a Dow Jones ESG badge
First-time inclusion in the DJBIC World Index, with S&P Global CSA score rising from 71 to 81.
Alivus Life Sciences Q4 transcript adds colour, not surprise
The 83-page record of the May 15 concall confirms known numbers and elaborates on Dahej fire and CDMO timelines, but holds no incremental market-moving news.
Sai Life Sciences' Q4 transcript adds nothing new
Earnings call transcript for FY26 results is a routine documentation; results and summary were already disclosed.
Solara appoints bankers to explore options for loss-making ibuprofen unit
Base business hits eight-quarter high in revenue and EBITDA at 26% margins, but Vizag facility and ibuprofen drag persist. Debt-free target set for FY29.